iOnco Analytics  
MarketVIEW: CAR-T r/r B-ALL global market forecast

Published: May 2017

Acute Lymphoblastic Leukaemia (ALL) is a hematologic malignancy characterised by the proliferation and accumulation of lymphoid progenitor cells (lymphoblasts) or lymphocytes in the bone marrow, blood or in various extramedullary sites. ALL, which mainly affects the <20 yrs age group represents about 0.4% of all new cancer cases in the US with around 6500 new cases per year and ~1400 deaths (SEER, Cancer Stat Facts). Rates for ALL have been rising ~0.6% each year for the last 10 years although the 5-year survival rate shows an increasing trend.

Despite a plethora of treatment strategies and a relatively high cure rate in children (60-90%), the prognosis of those individuals with relapsing/refractory disease (r/r) is still poor. In adults, long term survival (5 year rates) are often below 10%. No current standard approach exists. CAR-T or Chimeric Antigen Receptor T cells are a promising new treatment intervention for r/r B-ALL with companies such as Novartis, Pfizer (Cellectis), Medimmune, Juno Therapeutics, and Kite Pharma involved in clinical studies. Recently, Novartis has received a FDA priority review for CTL019 (tisagenlecleucel-T) upon BLA filing for pediatric and young adult patients for r/r B-cell ALL.

This MarketVIEW product consists of a detailed Executive presentation (~130 slides) and MS-Excel workbook forecasting the commercial potential ($ 000s) of novel CAR-T therapies (per competitor) in both pediatric and adult r/r B-ALL(new cases) across 9 major Western markets to 2030. A patient-based flow methodology has been devised where three possible intervention scenarios for CAR-T introduction are visualized so that the optimum product positioning can be assessed. In addition, an up-to-date review of B-ALL disease background, epidemiology, current and future treatments is presented along with a comprehensive review of the CAR-T landscape. Pricing and cost effectiveness considerations are also discussed. All assumptions are clearly provided.


To order please contact your region account manager, buy "on-line" or order direct at:

IOMV074 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20% (from January 2017) Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2017 iOnco Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains